Literature DB >> 16427207

In vivo protection by the xanthate tricyclodecan-9-yl-xanthogenate against amyloid beta-peptide (1-42)-induced oxidative stress.

M Perluigi1, G Joshi, R Sultana, V Calabrese, C De Marco, R Coccia, D A Butterfield.   

Abstract

Considerable evidence supports the role of oxidative stress in the pathogenesis of Alzheimer's disease. One hallmark of Alzheimer's disease is the accumulation of amyloid beta-peptide, which invokes a cascade of oxidative damage to neurons that can eventually result in neuronal death. Amyloid beta-peptide is the main component of senile plaques and generates free radicals ultimately leading to neuronal damage of membrane lipids, proteins and nucleic acids. Therefore, interest in the protective role of different antioxidant compounds has been growing for treatment of Alzheimer's disease and other oxidative stress-related disorders. Among different antioxidant drugs, much interest has been devoted to "thiol-delivering" compounds. Tricyclodecan-9-yl-xanthogenate is an inhibitor of phosphatidylcholine specific phospholipase C, and recent studies reported its ability to act as a glutathione-mimetic compound. In the present study, we investigate the in vivo ability of tricyclodecan-9-yl-xanthogenate to protect synaptosomes against amyloid beta-peptide-induced oxidative stress. Gerbils were injected i.p. with tricyclodecan-9-yl-xanthogenate or with saline solution, and synaptosomes were isolated from the brain. Synaptosomal preparations isolated from tricyclodecan-9-yl-xanthogenate injected gerbils and treated ex vivo with amyloid beta-peptide (1-42) showed a significant decrease of oxidative stress parameters: reactive oxygen species levels, protein oxidation (protein carbonyl and 3-nitrotyrosine levels) and lipid peroxidation (4-hydroxy-2-nonenal levels). Our results are consistent with the hypothesis that modulation of free radicals generated by amyloid beta-peptide might represent an efficient therapeutic strategy for treatment of Alzheimer's disease and other oxidative-stress related disorders. Based on the above data, we suggest that tricyclodecan-9-yl-xanthogenate is a potent antioxidant and could be of importance for the treatment of Alzheimer's disease and other oxidative stress-related disorders.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16427207     DOI: 10.1016/j.neuroscience.2005.12.004

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  18 in total

1.  Oxidative stress and toxicity induced by the nucleoside reverse transcriptase inhibitor (NRTI)--2',3'-dideoxycytidine (ddC): relevance to HIV-dementia.

Authors:  Wycliffe O Opii; Rukhsana Sultana; Hafiz Mohmmad Abdul; Mubeen Ahmad Ansari; Avindra Nath; D Allan Butterfield
Journal:  Exp Neurol       Date:  2006-10-25       Impact factor: 5.330

2.  In vivo administration of D609 leads to protection of subsequently isolated gerbil brain mitochondria subjected to in vitro oxidative stress induced by amyloid beta-peptide and other oxidative stressors: relevance to Alzheimer's disease and other oxidative stress-related neurodegenerative disorders.

Authors:  Mubeen Ahmad Ansari; Gururaj Joshi; Quanzhen Huang; Wycliffe O Opii; Hafiz Mohmmad Abdul; Rukhsana Sultana; D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2006-09-08       Impact factor: 7.376

Review 3.  Tricyclodecan-9-yl-xanthogenate (D609) mechanism of actions: a mini-review of literature.

Authors:  Rao Muralikrishna Adibhatla; J F Hatcher; A Gusain
Journal:  Neurochem Res       Date:  2011-11-22       Impact factor: 3.996

4.  Protection by D609 through cell-cycle regulation after stroke.

Authors:  Rao Muralikrishna Adibhatla; James F Hatcher
Journal:  Mol Neurobiol       Date:  2010-02-12       Impact factor: 5.590

5.  Regulation of neural progenitor cell proliferation by D609: potential role for ERK.

Authors:  Haviryaji S G Kalluri; Anchal Gusain; Robert J Dempsey
Journal:  Mol Neurobiol       Date:  2012-12-30       Impact factor: 5.590

Review 6.  Delineating the mechanism of Alzheimer's disease A beta peptide neurotoxicity.

Authors:  Roberto Cappai; Kevin J Barnham
Journal:  Neurochem Res       Date:  2007-08-31       Impact factor: 3.996

7.  Neuroprotective activities of enzymatically hydrolyzed peptides from porcine hide gelatin.

Authors:  Shaoyun Wang; Deng-Shun Wang; Rui Wang
Journal:  Int J Clin Exp Med       Date:  2008-08-10

Review 8.  Oxidatively modified proteins in Alzheimer's disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis.

Authors:  Rukhsana Sultana; Marzia Perluigi; D Allan Butterfield
Journal:  Acta Neuropathol       Date:  2009-03-14       Impact factor: 17.088

9.  Multifunctional antioxidants for the treatment of age-related diseases.

Authors:  Hongxia Jin; James Randazzo; Peng Zhang; Peter F Kador
Journal:  J Med Chem       Date:  2010-02-11       Impact factor: 7.446

10.  Protective effects of phytoestrogen alpha-zearalanol on beta amyloid25-35 induced oxidative damage in cultured rat hippocampal neurons.

Authors:  Yi-Long Dong; Ping-Ping Zuo; Qing Li; Feng-Hua Liu; Shun-Ling Dai; Qin-Sheng Ge
Journal:  Endocrine       Date:  2007-12-05       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.